Nirmatrelvir combined with ritonavir for preventing and treating COVID-19

Stefanie Reis, Maria-Inti Metzendorf, Rebecca Kuehn, Maria Popp, Ildiko Gagyor, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel, Stefanie Reis, Maria-Inti Metzendorf, Rebecca Kuehn, Maria Popp, Ildiko Gagyor, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel

Abstract

Background: Oral nirmatrelvir/ritonavir (Paxlovid®) aims to avoid severe COVID-19 in asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and death. Due to its novelty, there are currently few published study results. It remains to be evaluated for which indications and patient populations the drug is suitable. OBJECTIVES: To assess the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid®) plus standard of care compared to standard of care with or without placebo, or any other intervention for treating COVID-19 and for preventing SARS-CoV-2 infection. To explore equity aspects in subgroup analyses. To keep up to date with the evolving evidence base using a living systematic review (LSR) approach and make new relevant studies available to readers in-between publication of review updates.

Search methods: We searched the Cochrane COVID-19 Study Register, Scopus, and WHO COVID-19 Global literature on coronavirus disease database, identifying completed and ongoing studies without language restrictions and incorporating studies up to 11 July 2022. This is a LSR. We conduct monthly update searches that are being made publicly available on the open science framework (OSF) platform.

Selection criteria: Studies were eligible if they were randomized controlled trials (RCTs) comparing nirmatrelvir/ritonavir plus standard of care with standard of care with or without placebo, or any other intervention for treatment of people with confirmed COVID-19 diagnosis, irrespective of disease severity or treatment setting, and for prevention of SARS-CoV-2 infection. We screened all studies for research integrity. Studies were ineligible if they had been retracted, or if they were not prospectively registered including appropriate ethics approval.

Data collection and analysis: We followed standard Cochrane methodology and used the Cochrane risk of bias 2 tool. We rated the certainty of evidence using the GRADE approach for the following outcomes: 1. to treat outpatients with mild COVID-19; 2. to treat inpatients with moderate-to-severe COVID-19: mortality, clinical worsening or improvement, quality of life, (serious) adverse events, and viral clearance; 3. to prevent SARS-CoV-2 infection in post-exposure prophylaxis (PEP); and 4. pre-exposure prophylaxis (PrEP) scenarios: SARS-CoV-2 infection, development of COVID-19 symptoms, mortality, admission to hospital, quality of life, and (serious) adverse events. We explored inequity by subgroup analysis for elderly people, socially-disadvantaged people with comorbidities, populations from LICs and LMICs, and people from different ethnic and racial backgrounds.

Main results: As of 11 July 2022, we included one RCT with 2246 participants in outpatient settings with mild symptomatic COVID-19 comparing nirmatrelvir/ritonavir plus standard of care with standard of care plus placebo. Trial participants were unvaccinated, without previous confirmed SARS-CoV-2 infection, had a symptom onset of no more than five days before randomization, and were at high risk for progression to severe disease. Prohibited prior or concomitant therapies included medications highly dependent on CYP3A4 for clearance and CYP3A4 inducers. We identified eight ongoing studies. Nirmatrelvir/ritonavir for treating COVID-19 in outpatient settings with asymptomatic or mild disease For the specific population of unvaccinated, high-risk patients nirmatrelvir/ritonavir plus standard of care compared to standard of care plus placebo may reduce all-cause mortality at 28 days (risk ratio (RR) 0.04, 95% confidence interval (CI) 0.00 to 0.68; 1 study, 2224 participants; estimated absolute effect: 11 deaths per 1000 people receiving placebo compared to 0 deaths per 1000 people receiving nirmatrelvir/ritonavir; low-certainty evidence, and admission to hospital or death within 28 days (RR 0.13, 95% CI 0.07 to 0.27; 1 study, 2224 participants; estimated absolute effect: 61 admissions or deaths per 1000 people receiving placebo compared to eight admissions or deaths per 1000 people receiving nirmatrelvir/ritonavir; low-certainty evidence). Nirmatrelvir/ritonavir plus standard of care may reduce serious adverse events during the study period compared to standard of care plus placebo (RR 0.24, 95% CI 0.15 to 0.41; 1 study, 2224 participants; low-certainty evidence). Nirmatrelvir/ritonavir plus standard of care probably has little or no effect on treatment-emergent adverse events (RR 0.95, 95% CI 0.82 to 1.10; 1 study, 2224 participants; moderate-certainty evidence), and probably increases treatment-related adverse events such as dysgeusia and diarrhoea during the study period compared to standard of care plus placebo (RR 2.06, 95% CI 1.44 to 2.95; 1 study, 2224 participants; moderate-certainty evidence). Nirmatrelvir/ritonavir plus standard of care probably decreases discontinuation of study drug due to adverse events compared to standard of care plus placebo (RR 0.49, 95% CI 0.30 to 0.80; 1 study, 2224 participants; moderate-certainty evidence). No study results were identified for improvement of clinical status, quality of life, and viral clearance. Subgroup analyses for equity Most study participants were younger than 65 years (87.1% of the : modified intention to treat (mITT1) population with 2085 participants), of white ethnicity (71.5%), and were from UMICs or HICs (92.1% of study centres). Data on comorbidities were insufficient. The outcome 'admission to hospital or death' was investigated for equity: age (< 65 years versus ≥ 65 years) and ethnicity (Asian versus Black versus White versus others). There was no difference between subgroups of age. The effects favoured treatment with nirmatrelvir/ritonavir for the White ethnic group. Estimated effects in the other ethnic groups included the line of no effect (RR = 1). No subgroups were reported for comorbidity status and World Bank country classification by income level. No subgroups were reported for other outcomes. Nirmatrelvir/ritonavir for treating COVID-19 in inpatient settings with moderate to severe disease No studies available. Nirmatrelvir/ritonavir for preventing SARS-CoV-2 infection (PrEP and PEP) No studies available.

Authors' conclusions: There is low-certainty evidence that nirmatrelvir/ritonavir reduces the risk of all-cause mortality and hospital admission or death based on one trial investigating unvaccinated COVID-19 participants without previous infection that were at high risk and with symptom onset of no more than five days. There is low- to moderate-certainty evidence that nirmatrelvir/ritonavir is safe in people without prior or concomitant therapies including medications highly dependent on CYP3A4. Regarding equity aspects, except for ethnicity, no differences in effect size and direction were identified. No evidence is available on nirmatrelvir/ritonavir to treat hospitalized people with COVID-19 and to prevent a SARS-CoV-2 infection. We will continually update our search and make search results available on OSF.

Conflict of interest statement

  1. Stefanie Reis (SR) has no known conflicts of interest to declare.

  2. Maria‐Inti Metzendorf (MIM) has no known conflicts of interest to declare.

  3. Rebecca Kuehn (RK) has no known conflicts of interest to declare.

  4. Maria Popp (MP) has no known conflicts of interest to declare.

  5. Ildikó Gágyor (IG) has no known conflicts of interest to declare.

  6. Peter Kranke (PK) has no known conflicts of interest to declare.

  7. Patrick Meybohm (PM) has no known conflicts of interest to declare.

  8. Nicole Skoetz (NS) has no known conflicts of interest to declare.

  9. Stephanie Weibel (SW) has no known conflicts of interest to declare.

Copyright © 2022 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

Figures

1
1
PRISMA diagram
1.1. Analysis
1.1. Analysis
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 1: All‐cause mortality at day 28
1.2. Analysis
1.2. Analysis
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 2: Worsening of clinical status: admission to hospital or death at 28 days
1.3. Analysis
1.3. Analysis
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 3: Worsening of clinical status: admission to hospital or death at 28 days (subgroup analysis based on age)
1.4. Analysis
1.4. Analysis
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 4: Worsening of clinical status: admission to hospital or death at 28 days (subgroup analysis based on ethnicity)
1.5. Analysis
1.5. Analysis
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 5: Serious adverse events during the study period
1.6. Analysis
1.6. Analysis
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 6: Any grade treatment‐emergent adverse events during the study period
1.7. Analysis
1.7. Analysis
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 7: Any grade treatment‐related adverse events during the study period
1.8. Analysis
1.8. Analysis
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 8: Discontinuation of study drug due to adverse events during the study period

References

References to studies included in this review EPIC‐HR 2021 {published data only}

    1. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al, EPIC-HR Investigators. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. New England Journal of Medicine 2022;386:1397-408. [DOI: 10.1056/NEJMoa2118542]
    1. Norisuke K. jRCT2031210267: A study of PF-07321332/ritonavir in nonhospitalized high risk adult participants with COVID-19. 2021 (first received April 11 2022).
    1. Pfizer. 2021-002895-38: A phase 2/3 efficacy and safety study of PF-07321332 /ritonavir in nonhospitalized high risk adult participants with COVID 19. 2021 (first received April 11 2022).
    1. Pfizer. NCT04960202: EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19. 2021 (first received April 11 2022).
References to studies excluded from this review Caceres 2022 {published data only}
    1. Caceres J, Maki DG, Hennekens CH. Cautious optimism and considerations for health providers and patients: oral antiviral for early treatment of high-risk patients and vaccines for prevention of COVID-19. American Journal of Medicine 2022;135(7):808-9. [DOI: 10.1016/j.amjmed.2022.02.041]
Elliott 2022 {published data only}
    1. Elliott W, Chan J. Nirmatrelvir and ritonavir tablets (Paxlovid). Internal Medicine Alert 2022;44(1):Issue date: January 15, 2022.
EPIC‐PEDS 2022 {published data only}
    1. Pfizer Inc. A phase 2/3 safety, pharmacokinetics, and efficacy study of nirmatrelvir/ritonavir in pediatric, nonhospitalized symptomatic participantswWith COVID-19 who are at risk of progression to severe disease. 2022 (accessed May 15 2022).
NCT05305547 {published data only}
    1. Shionogi Clinical Trials Administrator. NCT05305547. A study to compare S-217622 with placebo in non-hospitalized high-risk participants with COVID-19. 2022 (accessed April 11 2022).
Singh 2022 {published data only}
    1. Singh RS, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, et al. Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir [online ahead of print]. Clinical Pharmacology & Therapeutics 2022. [DOI: 10.1002/cpt.2603]
    1. Singh Rsp, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, et al. Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. medRxiv 2022;2022.02.08:22270649. [DOI: 10.1101/2022.02.08.22270649]
Wang 2022 {published data only}
    1. Wang Z, Yang L. In the age of omicron variant: Paxlovid raises new hopes of COVID-19 recovery. Journal of Medical Virology 2022;94(5):1766-7. [DOI: 10.1002/jmv.27540]
References to ongoing studies ChiCTR2200059390 {published data only}
    1. ChiCTR2200059390. A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (covid-19) with high risk factors. (first received 28 April 2022).
EPIC‐PEP 2021 {published data only}
    1. Norisuke K. jRCT2031210349: A study of a potential oral treatment to prevent COVID-19 in adults who are exposed to household member(s) with a confirmed symptomatic COVID-19 infection. 2021.
    1. Pfizer. NCT05047601: A post-exposure prophylaxis study of PF-07321332/ritonavir in adult household contacts of an individual with symptomatic COVID-19. 2021.
    1. Pfizer Inc. EUCTR2021-002894-24-ES: A phase 2/3 postexposure prophylaxis study of PF-07321332/ritonavir in household contacts of a patient with COVID-19. 2021.
EPIC‐SR 2021 {published data only}
    1. Norisuke K. jRCT2031210274: A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. 2021.
    1. Pfizer. NCT05011513: A study of PF-07321332/ritonavir in non-hospitalized low-risk adult participants with COVID-19. 2021.
    1. Pfizer Inc. EUCTR2021-002857-28-HU: A phase 2/3 efficacy and safety study of PF-07321332/ritonavir in nonhospitalized low-risk adult participants with COVID-19. 2021.
NCT05321394 {published data only}
    1. Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19. Identifier: NCT05321394.
NCT05341609 {published data only}
    1. A multicenter, single-blind, randomized, controlled study to evaluate the efficacy and safety of JT001 (VV116) compared with Paxlovid for the early treatment of COVID-19 in participants with mild to moderate COVID-19. Identifier: NCT05341609.
NCT05386433 {published data only}
    1. NCT05386433. Paxlovid in the treatment of COVID-19 patients with uremia. (first received 23 May 2022).
PANORAMIC 2021 {published data only}
    1. ISRCTN30448031. A clinical trial investigating novel treatments for COVID-19 in the community. (first received 28 October 2021).
RECOVERY 2020 {published data only}
    1. University of Oxford. Randomised evaluation of COVID-19 therapy (RECOVERY). (first received 11 May 2020).
Additional references Agarwal 2020
    1. Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. BMJ 2020/09/04;370:m3379. [DOI: 10.1136/bmj.m3379]
Altulahi 2021
    1. Altulahi N, AlNujaim S, Alabdulqader A, Alkharashi A, AlMalki A, AlSiari F, et al. Willingness, beliefs, and barriers regarding the COVID-19 vaccine in Saudi Arabia: a multiregional cross-sectional study. BMC Family Practice 2021;22(1):247. [DOI: 10.1186/s12875-021-01606-6]
Amin 2021
    1. Amin SA, Banerjee S, Ghosh K, Gayen S, Jha T. Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorganic & Medicinal Chemistry 2021;29:115860. [PMID: ]
Anand 2003
    1. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300(5626):1763-7. [PMID: ]
Balshem 2011
    1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines – 3: rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PMID: ]
Booth 2021
    1. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLOS One 2021;16(3):e0247461. [PMID: ]
Bramstedt 2020
    1. Bramstedt KA. The carnage of substandard research during the COVID-19 pandemic: a call for quality. Journal of Medical Ethics 2020;46:803-7. [PMID: ]
CDC 2021
    1. Centers for Disease Control and Prevention (CDC). Benefits of getting a COVID-19 vaccine. (accessed 14 December 2021).
Chen 2010
    1. Chen S, Jonas F, Shen C, Hilgenfeld R. Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. Protein Cell 2010;1(1):59-74. [PMID: ]
Cochrane policy ‐ managing problematic studies
    1. Cochrane Database of Systematic Reviews: editorial policies. Cochrane policy on managing potentially problematic studies. (assessed 04 April 2022).
COMET 2020
    1. Core Outcome Measures in Effectiveness Trials (COMET) Initiative. Core outcome set developers’ response to COVID-19. (accessed 13 June 2021).
Dai 2020
    1. Dai W, Zhang B, Jiang X-M, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020;368(6497):1331-5. [PMID: ]
Data extraction template 2021
    1. Cochrane Pregnancy and Childbirth Group. pcg_data_extraction_form_v_2.2_-_13_july_2021_1.docx. (accessed 9 December 2021).
Deeks 2022
    1. Deeks JJ, Higgins JP, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from .
Deng 2020
    1. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. Journal of Infection 2020;81(1):e1-5. [PMID: ]
de Vries 2020
    1. Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O’Connor R, et al. Comparative study of a 3CL pro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models. bioRxiv 2020 ;95(10):1819-20. [DOI: 10.1101/2020.08.28.272880]
Dinnes 2021
    1. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al . Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database of Systematic Reviews 2021, Issue 3. Art. No: CD013705. [DOI: 10.1002/14651858.CD013705]
Eloy 2021
    1. Eloy P, Le Grand R, Malvy D, Guedj J. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two? eBioMedicine 2021;74:103663. [DOI: 10.1016/j.ebiom.2021.103663]
EndNote 2013 [Computer program]
    1. EndNote. Version EndNote 20. Philadelphia, PA: Clarivate, 2013.
EUA for Paxlovid
    1. US Food and Drug Administration (FDA). Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid. (accessed 14 February 2022).
Fajnzylber 2020
    1. Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nature Communications 2020;11(1):5493. [PMID: ]
Funk 2021
    1. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveillance 2021;26(16):2100348. [PMID: ]
German AWMF Guideline 2021
    1. Blankenfeld H, Kaduszkiewicz H, Kochen MM, Pömsl J. [SARS-CoV-2/Covid-19 Informationen und Praxishilfen für niedergelassene Hausärztinnen und Hausärzte]. (accessed 14 February 2022).
Gottlieb 2022
    1. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. New England Journal of Medicine 2022;386(4):305-15. [PMID: ]
Grant 2020
    1. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLOS One 2020;15(6):e0234765. [PMID: ]
Grey 2020
    1. Grey A, Bolland MJ, Avenell A, Klein AA, Gunsalus CK. Check for publication integrity before misconduct. Nature 2020;577(7789):167-9. [PMID: ]
Harvey 2021
    1. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology 2021;19(7):409-24. [PMID: ]
Higgins 2021
    1. Higgins JP, Lasserson T, Chandler J, Tovey D, Thomas J, Flemyng E, et al. Methodological Expectations of Cochrane Intervention Reviews (MECIR). (accessed 12 December 2021).
Higgins 2022a
    1. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from .
Higgins 2022b
    1. Higgins JP, Li T, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from .
Huang 2020
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. [PMID: ]
Huang 2021
    1. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397(10270):220-32. [PMID: ]
IntHout 2016
    1. IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 2016;12(6):e010247. [DOI: 10.1136/bmjopen-2015-010247] [PMID: ]
Juthani 2021
    1. Juthani PV, Gupta A, Borges KA, Price CC, Lee AI, Won CH, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infectious Diseases 2021;21(11):1485-6. [DOI: 10.1016/S1473-3099(21)00558-2]
Karagiannidis 2020
    1. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respiratory Medicine 2020;8(9):853-62. [PMID: ]
Kawasuji 2020
    1. Kawasuji H, Takegoshi Y, Kaneda M, Ueno A, Miyajima Y, Kawago K, et al. Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients. PLOS One 2020;15(12):e0243597. [PMID: ]
Killerby 2020
    1. Killerby ME, Link-Gelles R, Haight SC, Schrodt CA, England L, Gomes DJ, et al. Characteristics associated with hospitalization among patients with COVID-19 - Metropolitan Atlanta, Georgia, March–April 2020. Morbidity and Mortality Weekly Report 2020;69:790-4. [DOI: 10.15585/mmwr.mm6925e1]
Kumar 2020
    1. Kumar M, Al Khodor S. Pathophysiology and treatment strategies for COVID-19. Journal of Translational Medicine 2020;18(1):353. [DOI: 10.1186/s12967-020-02520-8]
Lefebvre 2022
    1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from .
Lin 2022
    1. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina. New England Journal of Medicine 2022;386(10):933-41. [PMID: ]
Liu 2020
    1. Liu Y, Yan L, Wan L, Xiang T, Le A, Liu J, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet 2020;20(6):656-7. [PMID: ]
Marshall 2020
    1. Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases 2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7] [PMID: ]
Merck 2021
    1. Merck. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by approximately 50 percent compared to placebo for patients with mild or moderate Covid-19 in positive interim analysis of phase 3 study. (accessed 1 October 2021).
Meta 2022 [Computer program]
    1. The R Project Meta: General Package for Meta-Analysis. Schwarzer G, Version 5.2-0. The R Project, 2022. Available at .
Metzendorf 2022
    1. Metzendorf MI, Weibel S, Reis S, McDonald S. A pragmatic and open science-based solution to a current problem in the reporting of Living Systematic Reviews – the Cochrane Review on nirmatrelvir/ritonavir (Paxlovid®). Manuscript submitted to publication, 2 June 2022.
MPP 2021a
    1. Medicines Patent Pool (MPP). Medicines Patent Pool. (accessed 1 December 2021).
MPP 2021b
    1. Medicines Patent Pool (MPP). Nirmatrelvir - License agreement; November 2021. Available at .
NCT04501978
    1. NCT04501978. ACTIV-3: Therapeutics for Inpatients with COVID-19 (TICO) [A multicenter, adaptive, randomized, blinded controlled trial of the safety and efficacy of investigational therapeutics for hospitalized patients with COVID-19]. (first received 6 August 2020).
NCT04535167
    1. NCT04535167. First-in-human study to evaluate safety, tolerability, and pharmacokinetics following single ascending and multiple ascending doses of PF-07304814 in hospitalized participants with COVID-19 [A phase 1B, 2-part, double-blind, placebo-controlled, sponsor-open study, to evaluate the safety, tolerability and pharmacokinetics of single ascending (24-hour, part 1) and multiple ascending (120-hour, part 2) intravenous infusions of PF-07304814 in hospitalized participants with COVID-19]. (first received 1 September 2020).
NCT04575597
    1. NCT04575597. Efficacy and safety of molnupiravir (MK-4482) in non-hospitalized adult participants with covid-19 (MK-4482-002) [A phase 2/3, randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy, safety, and pharmacokinetics of MK-4482 in non-hospitalized adults with COVID-19]. (first received 5 October 2020).
NHS 2021
    1. National Health Service (NHS) UK. Who cannot have vaccines. (accessed 14 December 2021).
NICE 2021
    1. National Institute for Health and Care Excellence (NICE). NG191: COVID-19 rapid guideline: managing COVID-19. (accessed 14 December 2021).
NIH 2021
    1. National Institutes of Health (NIH). COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. (accessed 14 December 2021).
Owen 2021
    1. Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 2021;374(6575):1586-93. [PMID: ]
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>;2-8]
Petrilli 2020
    1. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966. [PMID: ]
Pfizer 2021
    1. Pfizer Inc. Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. (accessed 23 November 2021).
Pfizer 2022
    1. Pfizer. Potentially Significant Drug Interactions, including Contraindicated DrugsPAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets). (accessed 20 May 2022) 2022;1.1:1-9.
Popp 2021a
    1. Popp M, Stegemann M, Metzendorf M-I, Gould S, Kranke P, Meybohm P, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub2]
Popp 2021b
    1. Popp M, Stegemann M, Riemer M, Metzendorf M-I, Romero CS, Mikollajewska A, et al. Antibiotics for the treatment of COVID-19. Cochrane Database of Systematic Reviews 2021, Issue 10. Art. No: CD015025. [DOI: 10.1002/14651858.CD015025]
Popp 2022
    1. Popp M, Reis S, Schießer S, Hausinger R Ilona, Stegemann M, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub3]
Reis 2022a
    1. Reis S, Metzendorf M, Kuehn R, Popp M, Gagyor I, Kranke P, et al. Living evidence base for Cochrane Review "Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19". (created 30 May 2022). [DOI: 10.17605/]
Ren 2022
    1. Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World Journal of Clinical Cases 2022;10(1):1-11. [PMID: ]
RevMan Web 2020 [Computer program]
    1. The Cochrane Collaboration Review Manager Web (RevMan Web). Version 1.22.0. The Cochrane Collaboration, 2020. Available at .
Salvatori 2020
    1. Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, et al. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. Journal of Translational Medicine 2020;18(1):222. [PMID: ]
Schünemann 2022
    1. Schünemann HJ, Higgins JPT Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from .
Shadmi 2020
    1. Shadmi E, Chen Y, Dourado I, Faran-Perach I, Furler J, Hangoma P, et al. Health equity and COVID-19: global perspectives. International Journal for Equity in Health 2020;19(1):104. [PMID: ]
Sterne 2019
    1. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. [DOI: 10.1136/bmj.l4898] [PMID: ]
Supplementary File_Nirmatrelvir_Research Integrity
    1. Weibel S, Reis S. Supplementary File_Nirmatrelvir_Research Integrity Assessment (Version 1). Zenodo 2022. [DOI: 10.5281/zenodo.7074190]
Supplementary File_Nirmatrelvir_Risk of Bias
    1. Weibel S, Reis S. Supplementary File_Nirmatrelvir_Risk of Bias Excel Tool (Version 1). Zenodo 2022. [DOI: 10.5281/zenodo.7074194]
Takashita 2022
    1. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, et al. Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant. New England Journal of Medicine 2022;386(10):995-8. [DOI: 10.1056/NEJMc2119407]
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [PMID: ]
Walls 2020
    1. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;183(6):1735. [PMID: ]
Wang 2021
    1. Wang C, Han B, Zhao T, Liu H, Liu B, Chen L, et al. Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: a national cross-sectional study. Vaccine 2021;39(21):2833-42. [PMID: ]
Watson 2020
    1. Watson J, Whiting PF, Brush JE. Interpreting a Covid-19 test result. BMJ 2020;369:m1808. [DOI: 10.1136/bmj.m1808]
Weibel 2022
    1. Weibel S, Popp M, Reis S, Skoetz N, Garner P, Sydenham E. Identifying and managing problematic trials: a Research Integrity Assessment (RIA) tool for randomized controlled trials in evidence synthesis. (first received 05 June 2022). [DOI: 10.1101/2022.05.31.22275756]
Welch 2012
    1. Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, et al. PRISMA-Equity 2012 Extension: reporting guidelines for systematic reviews with a focus on health equity. PLOS Medicine 2012;9(10):e1001333. [DOI: 10.1371/journal.pmed.1001333]
Wen 2022
    1. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Annals of Medicine 2022;54(1):516-23. [DOI: 10.1080/07853890.2022.2034936]
WHO 2018
    1. World Health Organization (WHO). International standards for clinical trial registries – 2nd edition. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Available at .
WHO 2020
    1. World Health Organization (WHO). Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). (accessed 24 November 2021).
WHO 2020a
    1. World Health Organization (WHO). Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. (accessed 8 April 2020).
WHO 2021
    1. World Health Organization (WHO). Vaccine equity. (accessed 14 December 2021).
WHO 2021a
    1. World Health Organization (WHO). WHO coronavirus disease (COVID-19) dashboard. (accessed 23 May 2022).
WHO 2021b
    1. World Health Organization (WHO). Therapeutics and COVID-19: living guideline . 24 September 2021 (accessed 23 May 2022);version 6:15-23.
Williamson 2020
    1. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584(7821):430-6. [PMID: ]
World Bank 2022
    1. World Bank. The world by income and region. (accessed 15 February 2022).
Wu 2020
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239-42. [PMID: ]
Zhang 2020
    1. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020;368(6489):409-12. [PMID: ]
Zhang 2021
    1. Zhang Y, Tang LV. Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication. Journal of Proteome Research 2021;20(1):49-59. [PMID: ]
References to other published versions of this review Reis 2022
    1. Reis S, Popp M, Kuehn R, Metzendorf M-I, Gagyor I, Kranke P, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19. Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No: CD015395. [DOI: 10.1002/14651858.CD015395]

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅